The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immune checkpoint inhibition-induced myocarditis in cancer patients: Proposal of a detection and management strategy.
 
Anjali Rao
No Relationships to Disclose
 
Vlad Zaha
No Relationships to Disclose
 
Bonnie Bermas
No Relationships to Disclose
 
John Lohrey
No Relationships to Disclose
 
Kevin Dale Courtney
Stock and Other Ownership Interests - Regeneron (I)
Consulting or Advisory Role - Exelixis
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma; Astellas Pharma (Inst); Astellas Pharma (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); Exelixis (Inst); Lilly (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Proacta (Inst); Stemline Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - My spouse receives patent royalties from Athena Diagnostics, Inc. (I)
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Corvus Pharmaceuticals; exelixis; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
David E. Gerber
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Samsung Bioepis
Research Funding - AstraZeneca (Inst); BerGenBio (Inst); Karyopharm Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending: “Prediction and Treatment of Immunotherapeutic Toxicity” (provisional, application number 62/461,455) (Inst); Royalties from Decision Support in Medicine from the Clinical Decision Support--Oncology on-line program.; Royalties from Oxford University Press from two books.
 
Sonia Garg
No Relationships to Disclose
 
Pradeep P Mammen
No Relationships to Disclose